Key clinical point: A molecular subtype-guided treatment based on four triple-negative breast cancer (TNBC) subtypes nearly doubled progression-free survival (PFS) outcomes compared with control therapy with nab-paclitaxel and had a favorable safety profile in patients with metastatic TNBC.
Major finding: Patients who received nab-paclitaxel + subtype-based therapy vs only nab-paclitaxel had significantly longer progression-free survival (median 11.3 months vs 5.8 months; hazard ratio 0.44; P < .0001). Neutropenia (30% vs 23%), anemia (7% vs none), and increased alanine aminotransferase (6% vs 1%) were the most common types of grade 3-4 treatment-related adverse events in the subtype-based group vs control group.
Study details: Findings are from the ongoing phase 2 FUTURE-SUPER trial that included 139 women age 18-70 years with metastatic or recurrent TNBC who were randomly assigned to receive a nab-paclitaxel + subtype-based regimen or only nab-paclitaxel .
Disclosures: This study was supported by Jiangsu Hengrui Pharmaceuticals, the National Key Research and Development Project of China, and other sources. Two authors declared being employees of Jiangsu Hengrui Pharmaceuticals.
Source: Fan L et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): A multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024 (Jan 8). doi: 10.1016/S1470-2045(23)00579-X